-If approved, more than 1,200 children would be newly eligible for a medicine that could treat the underlying cause of their disease- BOSTON-- (BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated ...

Trikafta is crucial for Vertex’s long-term growth as it has the potential to treat up to 90% of CF patients. The drug is under review in Europe with an approval expected later in 2020.

Shares of Vertex have rallied 22.3% so far this year against the industry ’s decline of 23.2%. Image Source: Zacks Investment Research Vertex holds a dominant position in the CF market.

Vertex Pharmaceuticals Incorporated VRTX announced FDA approval for its cystic fibrosis drug, Kalydeco (ivacaftor), for expanded use in children aged 12 months to two years.

Vertex receives European approval for Symkevi with Kalydeco for eligible children with cystic fibrosis ages 6-11 years ...

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has extended the licence of Vertex Pharmaceuticals’ cystic fibrosis drugs for children aged two to five years. The treatments, Kaftrio ...

Vertex holds a dominant position in the CF market. Trikafta/Kaftrio generated revenues of $6.61 billion in the first nine months of 2023, accounting for almost 90% of the company’s total product ...

The approval was based on data from an ongoing phase III study, ARRIVAL, evaluating 25 children who have one of 10 mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. A ...